Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYN818 in advanced solid tumors
NCT06666270Phase 1Recruiting
- Sponsor
- SynRx Therapeutics
- Start
- Nov 2024
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SYN818 in solid tumor (advanced stage), breast cancer, ovarian cancer and 1 more, sponsored by SynRx Therapeutics. Primary endpoints: Number of participants with Dose Limiting Toxicities, Number of participants experiencing adverse events (AEs)/serious adverse events (SAEs) up to 3 years and 1 more. Started Nov 2024; status: recruiting.
02
Drugs
SYN818
03
Conditions
solid tumor (advanced stage)breast cancerovarian cancerprostate cancer (PCa)
Beyond the preview
Go deeper on NCT06666270.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06666270.